Septic shock is a common emergency, most often caused by gram-negative bacteremia. Appearance of gram-negative endotoxin in the systemic circulation sets off a complex reaction involving many physiologic systems. The resultant reduction in microcirculation and subsequent organ dysfunction often lead to death. Early therapy to support the cardiovascular system and rational antibiotic therapy may improve the chance of survival. Careful monitoring of disease and drug effect parameters is essential to therapy.
DaleD.C.Infections in the compromised host. In: IsselbacherK.J., AdamsR.D., BraunwaldE., PetersdorfR.G., WilsonJ.D., eds. Harrison's principles of internal medicine. 9th ed. New York: McGraw-Hill, 1980: 552–6.
8.
HessM.L., HastilloA., GreenfieldL.J.Spectrum of cardiovascular function during gram-negative sepsis. Prog Cardiovasc Dis1981; 23: 279–98.
9.
HardawayR.M., JamesP.M., AndersonR.W.Intensive study and treatment of shock in man. JAMA1967; 199: 799–802.
10.
HardawayR.M.Monitoring of the patient in a state of shock. Surg Gynecol Obstet1979; 148: 339–45.
11.
JakschikB.A., MarshallG.R., KomrixJ.S.Profile of circulating vasoactive substances in hemorrhagic shock and their pharmacologic manipulation. J Clin Invest1974; 54: 842–52.
12.
ClowesG.H., FarringtonG.H., ZuschneidW.Circulating factors in the etiology of pulmonary insufficiency and right heart failure accompanying severe sepsis (peritonitis). Ann Surg1970; 171: 663–78.
LeferA.M.Properties of cardioinhibitory factors produced in shock. Fed Proc1978; 37: 2734–40.
15.
MaksadA.K., ChaC.J., StuartR.C.Myocardial depression in septic shock: physiologic and metabolic effects of a plasma factor on an isolated heart. Recent Adv Shock Res1979; 1: 35–42.
16.
ClowesG.H.A., O'DonnellT.F., RyanN.T.Energy metabolism in sepsis: treatment based on different patterns in shock and high output stage. Ann Surg1974; 179: 684–94.
17.
SeigelJ.H., CerraF.B., ColemanB.Physiological and metabolic correlations in human sepsis. Surgery1979; 86: 163–93.
FrankM.M.The complement system in host disease and inflammation. Rev Infect Dis1979; 1: 483–501.
20.
Muller-EberhardH.J.Complement. Annu Rev Biochem1975; 44: 697–724.
21.
FearonD.T., RuddyS., SchurP.H.Activation of the properdin pathway of complement in patients with gram-negative bacteremia. N Engl J Med1975; 292: 937–40.
BickR.L.Disseminated intravascular coagulation and related syndromes: etiology, pathophysiology, diagnosis, and management. Am J Hematol1978; 5: 265–82.
31.
MuranoG.The “Hageman connection”: interrelationships of blood coagulation, fibrino-(geno) lysis, kinin generation, and complement activation. Am J Hematol1978; 4: 409–17.
32.
ColemanR.W., WongP.Y.Participation of Hageman factor-dependent pathways in human disease states. Thromb Haemos1977; 35: 751–75.
33.
RatnoffO.D., SaitoH.Interactions among Hageman factor, plasma kallikrein, high molecular weight kininogen, and plasma thromboplastin antecedent. Proc Natl Acad Sci USA1979; 76: 958–61.
34.
SatterwhiteT.K., HawigerJ., BurklowS.L.Degradation products of fibrinogen and fibrin in bacteremia due to gram-negative rods. J Infect Dis1973; 127: 437–41.
35.
LucieN.P., BrowningJ.D., SmillieD.M., LedinghamI.M.Platelet count and other haematologic measurements in septic shock. J Clin Pathol1980; 33: 890–6.
36.
ShubinH., WeilM.H., CarlsonR.W.Bacterial shock. Am Heart J1977; 94: 112–4.
37.
RobinsonW.A.Fluid therapy in hemorrhagic shock. Crit Care Q1980; 2: 1–13.
38.
PuriV.K., PaidipatyB., WhiteL.Hydroxyethyl starch for resuscitation of patients with hypovolemia and shock. Crit Care Med1981; 9: 833–7.
39.
YoungL.S.Gram-negative sepsis. In: MandellG.L., DouglasR.G., BennettJ.E., eds. Principles and practice of infectious diseases.New York: Wiley and Sons, 1979: 571–608.
40.
KlasterskyJ.Prediction and significance of synergy between antibiotics used for treatment of gram-negative sepsis. Infection1980; 8(suppl 1): 545–8.
41.
RahalJ.J.Antibiotic combinations: the clinical relevance of synergy and antagonism. Medicine1978; 57: 179–95.
42.
ReevesD.S.Therapeutic drug monitoring of aminoglycoside antibiotics. Infection1980; 8(suppl 3): 5513–20.
43.
SawchukR.J., ZaskeD.E., CipolleR.J.Kinetic model for gentamicin dosing with the use of individual parameters. Clin Pharmacol Ther1977; 21: 362–9.
SarubbiF.A., HullJ.H.Amikacin serum concentrations: prediction of level and dosage guidelines. Ann Intern Med1980; 89: 612–8.
46.
ChowM., DeglinJ., HarralsonA.Prediction of gentamicin serum levels using a one-compartment open linear pharmacokinetic model. Am J Hosp Pharm1978; 35: 1078–81.
47.
TozerT.N.Nomogram for modification of dosage regimens in patients with chronic renal function impairment. J Pharmacokinet Biopharm1974; 2: 13–18.
48.
PlattD.R., MatthewsS.J., SevkaM.J.Comparison of four methods of predicting serum gentamicin concentrations in adult patients with impaired renal function. Clin Pharm1982; 1: 361–5.
49.
PlachetkaJ.R.Sympathomimetic pharmacology. Crit Care Q1980; 2: 27–35.
50.
WilsonR.F., SibbaldW.J., JaanimagiJ.L.Hemodynamic effects of dopamine in critically ill patients. J Surg Res1976; 20: 163–70.
51.
SmithT.E., ForgacsP.Haemodynamic interventions and therapy in septic shock. Drugs1982; 24: 75–82.
52.
HardawayR.M.Treatment of severe shock with phenoxybenzamine. Surg Gynecol Obstet1980; 151: 725–34.
53.
GuglielmoB.J.Evaluation of the use of corticosteroids. Crit Care Q1980; 2: 37–42.
54.
KlasterskyJ., CappelR., DebusseherL.Effectiveness of dexamethasone in management of severe infections. N Engl J Med1971; 284: 1248–50.
55.
KregerB.E., CravenD.E., McCabeW.R.Gram-negative bacteremia. IV. Re-evaluation of clinical features and treatment in 612 patients. Am J Med1980; 68: 344–55.
56.
SchumerW.Steroids in the treatment of clinical septic shock. Arch Surg1976; 98: 259–61.
57.
SibbaldW.J., AndersonR.R., ReidB., HollidayP.C., DreigerA.A.Alveolar-capillary permeability in human septic ARDS. Chest1981; 79: 133–47.
58.
PetersW.P., FriedmanP.A., JohnsonM.W., MitchW.E.Pressor effect of naloxone in septic shock. Lancet1981; 1: 529–32.
59.
SwinburnW.R., PhelanP.Response of naloxone in septic shock. Lancet1982; 1: 167.
60.
RaymondR.M., HarkemaJ.M., StoffsW.V., EmersonT.E.Effects of naloxone therapy on hemodynamics and metabolism following a superlethal dosage of Escherichia coli endotoxin in dogs. Surg Gynecol Obstet1981; 152: 159–62.
61.
FadenA.I., HoladayJ.W.Experimental endotoxin shock: the pathophysiologic function of endorphins and treatment with opiate antagonists. J Infect Dis1980; 142: 229–38.
62.
ForresterJ.S., DiamondG.A., SwanH.J.C.Bedside diagnosis of latent cardiac complications in acutely ill patients. JAMA1972; 222: 59–63.
63.
HardawayR.M.Prediction of survival or death of patients in a state of septic shock. Surg Gynecol Obstet1981; 152: 200–6.
